20 Dec 2021 argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Member news
10 Dec 2021 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis Member news
08 Dec 2021 MRM Health announces first patient dosed with next generation live microbiome consortia therapeutic MH002 in Phase 1b/2a study in patients with Ulcerative Colitis Member news
07 Dec 2021 Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study Member news
07 Dec 2021 Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion Member news
06 Dec 2021 Celyad Oncology announces $32.5 million private placement with Fortress Investment Group Member news
06 Dec 2021 New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster Member news
More info? Ellen Telleir Communication Coordinator linkedin.com/in/ellentelleir/ +32 9 241 80 41 ellen.telleir@flanders.bio Contact us
